Raiffeisen Bank International AG Acquires New Stake in DaVita Inc. (NYSE:DVA)

Raiffeisen Bank International AG purchased a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 2,477 shares of the company's stock, valued at approximately $371,000.

Several other large investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new position in DaVita during the 4th quarter worth approximately $41,000. Coppell Advisory Solutions LLC boosted its stake in shares of DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company's stock valued at $45,000 after buying an additional 100 shares in the last quarter. Canada Post Corp Registered Pension Plan purchased a new stake in shares of DaVita in the fourth quarter valued at approximately $55,000. Venturi Wealth Management LLC grew its holdings in DaVita by 59.8% during the fourth quarter. Venturi Wealth Management LLC now owns 406 shares of the company's stock worth $61,000 after acquiring an additional 152 shares during the period. Finally, Blue Trust Inc. raised its position in DaVita by 39.7% in the fourth quarter. Blue Trust Inc. now owns 461 shares of the company's stock worth $76,000 after acquiring an additional 131 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

NYSE DVA traded down $0.98 during trading hours on Friday, reaching $137.55. The company's stock had a trading volume of 109,695 shares, compared to its average volume of 826,179. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The company's 50-day moving average is $145.54 and its two-hundred day moving average is $153.41. DaVita Inc. has a fifty-two week low of $131.44 and a fifty-two week high of $179.60. The stock has a market cap of $10.38 billion, a PE ratio of 12.82, a PEG ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a net margin of 7.31% and a return on equity of 115.48%. The company had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. During the same quarter in the prior year, the firm earned $2.26 earnings per share. The company's revenue for the quarter was up 5.0% compared to the same quarter last year. Analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

DVA has been the topic of several research analyst reports. Barclays boosted their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Cowen reiterated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research report on Friday, February 21st. Truist Financial reduced their price target on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday. Finally, Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, DaVita presently has an average rating of "Hold" and a consensus price target of $164.50.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.